The present study aims to update the use of novel antidiabetic molecules (DPP4-i, GLP-1 Ra, SGLT2-i) in T2DM and COVID-19 patients by highlighting primary and secondary outcomes from clinical studies and underlying possible molecular mechanisms. This evidence concerns the gene GCG and type 2 diabetes mellitus.